Response Rate And Local Recurrence After Concurrent Immune Checkpoint Therapy And Radiation For Non-Small Cell Lung Cancer And Melanoma Brain Metastases
Jack M. Qian(South Shore Hospital), Ayal A. Aizer(Brigham and Women's Hospital), F. Stephen Hodi(Harvard University), A. Daniel Martin(University of Toledo), J.D. Schoenfeld(Dana-Farber Cancer Institute), Paul J. Catalano(Computational Physics (United States)), Kate Martin(Harvard University)
International Journal of Radiation Oncology*Biology*Physics
October 23, 2020
Cited by 2
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k